Analysts’ Weekly Ratings Changes for Thermo Fisher Scientific (TMO)

A number of firms have modified their ratings and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) recently:

• 10/30/2026 – Thermo Fisher Scientific had its price target raised by Argus from $560.00 to $780.00. They now have a “buy” rating on the stock.
• 10/28/2026 – Thermo Fisher Scientific had its price target lowered by Evercore from $720.00 to $615.00. They now have an “outperform” rating on the stock.
• 10/23/2026 – Thermo Fisher Scientific had its price target raised by Citigroup from $685.00 to $800.00. They now have a “buy” rating on the stock.
• 10/23/2026 – Thermo Fisher Scientific was downgraded by DZ Bank from “strong-buy” to “hold”.
• 10/22/2026 – Thermo Fisher Scientific had its “buy” rating reaffirmed by UBS Group. They now have a $800.00 price target on the stock, up from $540.00.
• 10/22/2026 – Thermo Fisher Scientific had its price target raised by Royal Bank Of Canada from $580.00 to $730.00. They now have a “sector perform” rating on the stock.
• 10/22/2026 – Thermo Fisher Scientific had its price target raised by Barclays from $750.00 to $775.00. They now have an “overweight” rating on the stock.
• 10/22/2026 – Thermo Fisher Scientific had its price target raised by Deutsche Bank from $720.00 to $750.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Thermo Fisher Scientific had its price target raised by Rothschild & Co Redburn from $725.00 to $750.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Thermo Fisher Scientific had its price target raised by TD Cowen from $760.00 to $810.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Thermo Fisher Scientific had its price target raised by Stifel Nicolaus from $650.00 to $775.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Thermo Fisher Scientific had its price target raised by Robert W. Baird from $723.00 to $756.00. They now have an “outperform” rating on the stock.
• 10/15/2026 – Thermo Fisher Scientific was given a new $740.00 price target by Royal Bank Of Canada.
• 10/15/2026 – Thermo Fisher Scientific is now covered by Guggenheim. They set a “buy” rating and a $740.00 price target on the stock.
• 10/15/2026 – Thermo Fisher Scientific had its “buy” rating reaffirmed by Guggenheim. They now have a $740.00 price target on the stock.
• 10/14/2026 – Thermo Fisher Scientific had its price target raised by JPMorgan Chase & Co. from $690.00 to $760.00. They now have an “overweight” rating on the stock.
• 10/13/2026 – Thermo Fisher Scientific had its price target raised by TD Cowen from $675.00 to $760.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Thermo Fisher Scientific had its price target raised by Morgan Stanley from $650.00 to $730.00. They now have an “overweight” rating on the stock.
• 10/8/2026 – Thermo Fisher Scientific was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 10/7/2026 – Thermo Fisher Scientific had its price target raised by Barclays from $650.00 to $750.00. They now have an “overweight” rating on the stock.
• 10/3/2026 – Thermo Fisher Scientific was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/25/2026 – Thermo Fisher Scientific had its “buy” rating reaffirmed by Deutsche Bank. They now have a $720.00 price target on the stock.
• 9/21/2026 – Thermo Fisher Scientific had its price target raised by The Goldman Sachs Group from $650.00 to $780.00. They now have a “buy” rating on the stock.

Thermo Fisher Scientific Trading Up 0.1%

NYSE:TMO traded up $0.54 on Friday, reaching $699.98. The company’s stock had a trading volume of 1,837,337 shares, compared to its average volume of 2,254,235. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $727.56. The business’s 50-day moving average price is $670.82 and its two-hundred day moving average price is $556.81. The firm has a market cap of $259.36 billion, a PE ratio of 36.92, a PEG ratio of 2.92 and a beta of 0.84. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the previous year, the firm posted $5.79 earnings per share. The business’s revenue was up 9.1% on a year-over-year basis. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.27 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Tuesday, December 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.92%.

Insider Activity at Thermo Fisher Scientific

In related news, VP Lisa Britt sold 11,440 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. This trade represents a 7.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 24,546 shares of company stock valued at $15,479,192 over the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.